Compare SHASUN PHARMA with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs NOVARTIS - Comparison Results

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA NOVARTIS SHASUN PHARMA/
NOVARTIS
 
P/E (TTM) x 123.9 524.2 23.6% View Chart
P/BV x 8.5 29.4 29.0% View Chart
Dividend Yield % 0.2 1.5 15.5%  

Financials

 SHASUN PHARMA   NOVARTIS
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
NOVARTIS
Mar-19
SHASUN PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs94980 9.6%   
Low Rs46600 7.6%   
Sales per share (Unadj.) Rs214.2198.7 107.8%  
Earnings per share (Unadj.) Rs5.321.0 25.4%  
Cash flow per share (Unadj.) Rs15.822.3 71.1%  
Dividends per share (Unadj.) Rs1.0010.00 10.0%  
Dividend yield (eoy) %1.41.3 113.0%  
Book value per share (Unadj.) Rs53.3307.5 17.3%  
Shares outstanding (eoy) m56.6224.69 229.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.0 8.2%   
Avg P/E ratio x13.137.7 34.8%  
P/CF ratio (eoy) x4.435.5 12.4%  
Price / Book Value ratio x1.32.6 51.0%  
Dividend payout %18.747.7 39.3%   
Avg Mkt Cap Rs m3,95819,508 20.3%   
No. of employees `000NA0.6 0.0%   
Total wages/salary Rs m2,1641,171 184.7%   
Avg. sales/employee Rs ThNM8,445.4-  
Avg. wages/employee Rs ThNM2,015.7-  
Avg. net profit/employee Rs ThNM891.0-  
INCOME DATA
Net Sales Rs m12,1274,907 247.1%  
Other income Rs m229783 29.3%   
Total revenues Rs m12,3565,689 217.2%   
Gross profit Rs m1,009123 821.7%  
Depreciation Rs m59432 1,866.7%   
Interest Rs m41516 2,610.7%   
Profit before tax Rs m230858 26.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-73340 -21.4%   
Profit after tax Rs m302518 58.4%  
Gross profit margin %8.32.5 332.5%  
Effective tax rate %-31.739.6 -79.9%   
Net profit margin %2.510.6 23.6%  
BALANCE SHEET DATA
Current assets Rs m6,8848,055 85.5%   
Current liabilities Rs m8,4561,850 457.1%   
Net working cap to sales %-13.0126.4 -10.2%  
Current ratio x0.84.4 18.7%  
Inventory Days Days6245 136.9%  
Debtors Days Days10834 317.1%  
Net fixed assets Rs m4,970150 3,317.9%   
Share capital Rs m113123 91.8%   
"Free" reserves Rs m2,8757,469 38.5%   
Net worth Rs m3,0207,592 39.8%   
Long term debt Rs m1,8170-   
Total assets Rs m13,3479,824 135.9%  
Interest coverage x1.654.9 2.8%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.90.5 181.9%   
Return on assets %5.45.4 98.9%  
Return on equity %10.06.8 146.7%  
Return on capital %13.311.5 115.8%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84358 10,143.4%   
Fx outflow Rs m2,1731,326 163.8%   
Net fx Rs m3,669-1,269 -289.2%   
CASH FLOW
From Operations Rs m398-1,943 -20.5%  
From Investments Rs m-1,6352,742 -59.6%  
From Financial Activity Rs m1,309-298 -438.8%  
Net Cashflow Rs m71501 14.2%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 3.6 2.0 180.0%  
FIIs % 17.6 1.6 1,100.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 21.5 184.2%  
Shareholders   20,750 41,647 49.8%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   PIRAMAL ENTERPRISES  GSK PHARMA  DR. DATSONS LABS  DR. REDDYS LAB  ABBOTT INDIA  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY19); Net Profit Up 42.2% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, NOVARTIS has posted a net profit of Rs 100 m (up 42.2% YoY). Sales on the other hand came in at Rs 1 bn (up 20.3% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS